Drugs / Hydronidone
Hydronidone
Trials 16 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT07471217 | Apr → Jul 2026 overdue | fibrotic liver disease | Beijing Continent Pharmaceutical Co, Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07394309 | Feb 2026 overdue | fibrotic liver disease | Beijing Continent Pharmaceutical Co, Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07263152 | Dec 2025 → Feb 2026 | fibrotic liver disease | Beijing Continent Pharmaceutical Co, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07262333 | Dec 2025 → Jul 2026 overdue | chronic kidney disease | Beijing Continent Pharmaceutical Co, Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07262346 | Dec 2025 → May 2026 overdue | fibrotic liver disease | Beijing Continent Pharmaceutical Co, Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT04162821 | Oct → Nov 2019 | — | Beijing Continent Pharmaceutical Co, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04123769 | Sep 2019 → Oct 2020 | chronic hepatitis B virus infection | Beijing Continent Pharmaceutical Co, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04124081 | May → Jun 2019 | — | Beijing Continent Pharmaceutical Co, Ltd. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07417553 | Apr → Jul 2026 overdue | fibrotic liver disease | Beijing Continent Pharmaceutical Co, Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07364448 | Mar → Jul 2026 overdue | chronic hepatitis B virus infection | Beijing Continent Pharmaceutical Co, Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT02499562 | Jun 2015 → Nov 2020 | chronic hepatitis B virus infection | Shanghai Genomics, Inc. | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07343778 | Mar → Oct 2026 expected | chronic hepatitis B virus infection | Beijing Continent Pharmaceutical Co, Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07412236 | Jan 2026 → Dec 2028 expected | fibrotic liver disease | Beijing Continent Pharmaceutical Co, Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05905172 | Aug 2023 → Jun 2028 expected | fibrotic liver disease | Beijing Continent Pharmaceutical Co, Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05115942 | Dec 2021 → Oct 2024 | fibrotic liver disease | Beijing Continent Pharmaceutical Co, Ltd. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04125056 | Jan 2019 | — | Beijing Continent Pharmaceutical Co, Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hydronidone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07262346 ↗ |
| Known as | F 351 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297288 ↗ |
| Known as | Hydronidone capsules | “Drug: Hydronidone capsules” NCT07364448 ↗ |
| Modality | Small molecule | “Hydronidone capsules are pyridinone-based small molecule compounds.” NCT07262333 ↗ |
| Route | Oral | “hydronidone orally (180 mg/day, 270 mg/day, or 360 mg/day)” PMID 35842120 ↗ Jul 2022 |